Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Pharmacology and Experimental Therapeutics|April 11, 2009
The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonistsKathryn A Seely, Mark S Levi, Paul L Prather
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 8, 2012
Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoidsKathryn A Seely, Jeff Lapoint, Jeffery H Moran, et al.
Molecular Interventions|March 29, 2011
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?Kathryn A Seely, Paul L Prather, Laura P James, et al.
Journal of Neurochemistry|January 24, 2007
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJennifer L Shoemaker, Kathryn A Seely, Ronald L Reed, et al.
Ecotoxicology and Environmental Safety|May 24, 2021
Association between pesticide exposure and colorectal cancer risk and incidence: A systematic reviewEryn K Matich, Jonathan A Laryea, Kathryn A Seely, et al.
International Journal of Analytical Chemistry|April 16, 2015
A High Throughput Method for Measuring Polycyclic Aromatic Hydrocarbons in Seafood Using QuEChERS Extraction and SBSEEdward A Pfannkoch, John R Stuff, Jacqueline A Whitecavage, et al.
The American Journal of Pathology|November 29, 2011
Development of oxidative stress in the peritubular capillary microenvironment mediates sepsis-induced renal microcirculatory failure and acute kidney injuryZhen Wang, Joseph H Holthoff, Kathryn A Seely, et al.
Neuropharmacology|July 10, 2012
AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studiesKathryn A Seely, Lisa K Brents, Lirit N Franks, et al.
Chemical Research in Toxicology|March 13, 2012
A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptorsKathryn A Seely, Lisa K Brents, Anna Radominska-Pandya, et al.
Pageof 3